Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableNot Yet RecruitingNCT06950671
What this trial is testing

Role of Triggering Receptor Expressed on Myeloid Cells (TREM-1) as a Novel Biomarker in Human Epidermal Growth Factor Receptor -2 (HER-2) Negative Breast Cancer: a Molecular and Clinical Study

Who this might be right for
Breast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage III+1 more
Rahma Esam Salama Esawi 1
Not applicableStudy completedNCT07115095
What this trial is testing

Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Nanlin Li 98
Not applicableLooking for participantsNCT07281001
What this trial is testing

Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

Who this might be right for
HER2-positive Breast CancerTrastuzumab Deruxtecan
Blokhin's Russian Cancer Research Center 60
Large-scale testing (Phase 3)Ended earlyNCT02213744
What this trial is testing

MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients

Who this might be right for
Breast CancerHER2 Positive Breast Cancer
Merrimack Pharmaceuticals 113
Testing effectiveness (Phase 2)Looking for participantsNCT05594095
What this trial is testing

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Who this might be right for
Breast NeoplasmBreast CancerHormone Receptor Positive Tumor+2 more
Fudan University 620
Early research (Phase 1)Study completedNCT04176757
What this trial is testing

ZN-c5 in Participants With Breast Cancer

Who this might be right for
Breast Cancer
Zeno Alpha Inc. 35
Large-scale testing (Phase 3)Study completedNCT03493854
What this trial is testing

Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Who this might be right for
Early Breast Cancer
Hoffmann-La Roche 500
Testing effectiveness (Phase 2)Looking for participantsNCT05635487
What this trial is testing

SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Who this might be right for
HER2-positive Breast Cancer
Shengjing Hospital 65
Post-approval studies (Phase 4)WithdrawnNCT03988114
What this trial is testing

Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Large-scale testing (Phase 3)Active Not RecruitingNCT07386938
What this trial is testing

The Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
R-Pharm 246
Post-approval studies (Phase 4)Not Yet RecruitingNCT07589699
What this trial is testing

Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP

Who this might be right for
Breast CancerHER2-positive Breast CancerEarly-stage Breast Cancer+1 more
The First Affiliated Hospital with Nanjing Medical University 59
Not applicableNot Yet RecruitingNCT07187752
What this trial is testing

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

Who this might be right for
Breast Cancer
Shandong Cancer Hospital and Institute 1,039
Testing effectiveness (Phase 2)Active Not RecruitingNCT04053322
What this trial is testing

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

Who this might be right for
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancera Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
UNICANCER 172
Large-scale testing (Phase 3)Study completedNCT00615602
What this trial is testing

Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

Who this might be right for
Breast Cancer
Hellenic Oncology Research Group 489
Testing effectiveness (Phase 2)UnknownNCT04681287
What this trial is testing

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Who this might be right for
HER2 Positive Metastatic Breast Cancer
Henan Cancer Hospital 46
Not applicableActive Not RecruitingNCT06663787
What this trial is testing

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment

Who this might be right for
Breast Cancer, MetastaticHER2 + Breast Cancer
Nagoya City University 50
Large-scale testing (Phase 3)Looking for participantsNCT06313086
What this trial is testing

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 442
Not applicableUnknownNCT03617341
What this trial is testing

Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer With HER2 PositiveTriple Negative Breast Cancer
Yonsei University 200
Testing effectiveness (Phase 2)Ended earlyNCT03070002
What this trial is testing

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Who this might be right for
Breast Carcinoma Metastatic in the BoneCirculating Tumor Cell CountEstrogen Receptor Positive+3 more
Northwestern University 1
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07836257
What this trial is testing

A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd

Who this might be right for
Breast Cancer
Fujian Medical University 28
Next Page